Vigitel Brasil 2013: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. 2014.

Rigby N. Eating and obesity – the new world disorder. Nutrients. 2013;5(10):4206-10.

McGill AT. Causes of metabolic syndrome and obesity-related co-morbidities part 1: a compositeunifying theory review of human-specific co-adaptations to brain energy consumption. Arch Public Health. 2014;72(1):30.

Bonomini F, Rodella LF, Rezzani R. Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis. 2015;6(2):109-20.

The IDF consensus worldwide definition of the metabolic syndrome. 2005.

Kawada T, Andou T, Fukumitsu M. Metabolic syndrome showed significant relationship with carotid atherosclerosis. Heart Vessels. 2015.

Bhatt H, Safford M, Glasser S. Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the reasons for geographic and racial differences in stroke (REGARDS) study. Curr Hypertens Rep. 2015;17(4):541.

I Diretriz brasileira de diagnóstico e tratamento da síndrome metabólica. Arq Bras Cardiol. 2005;84(^sSupl 1):1-28.

Kaya E, Sikka SC, Gur S. A comprehensive review of metabolic syndrome affecting erectile dysfunction. J Sex Med. 2015;12(4):856-75.

Won KB, Chang HJ, Niinuma H. Inverse association between central obesity and arterial stiffness in Korean subjects with metabolic syndrome: a cross-sectional cohort study. Diabetol Metab Syndr. 2015;7:3.

Coffman E, Richmond-Bryant J. Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study. Popul Health Metr. 2015;13:7.

Teixeira AA, Marrocos MS, Quinto BM. Diversity of apolipoprotein E genetic polymorphism significance on cardiovascular risk is determined by the presence of Metabolic Syndrome among hypertensive patients. Lipids Health Dis. 2014;13(1):174.

Johnson KM, Dowe DA. Accuracy of statin assignment using the 2013 AHA/ACC Cholesterol Guideline versus the 2001NCEP ATP III guideline: correlation with atherosclerotic plaque imaging. J Am Coll Cardiol. 2014;64(9):910-9.

Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: an American Heart Association⁄National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.

Martocchia A, Stefanelli M, Falaschi GM, Toussan L, Ferri C, Falaschi P. Recent advances in the role of cortisol and metabolic syndrome in age-related degenerative diseases. Aging Clin Exp Res. 2015.

Abella V, Scotece M, Conde J. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol. 2014:343746.

Zeb I, Budoff M. Coronary artery calcium screening: does it perform better than other cardiovascular risk stratification tools?. Int J Mol Sci. 2015;16(3):6606-20.

Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular Diseases. Clin Med Insights Cardiol. 2015;8(^sSupl 3):23-33.

Blauth F, Lara GM, Wagner SC, César LR. Association between cardiovascular risk factors and C reactive protein in aged women. J Bras Patol Med Lab. 2008;44(2):83-8.

Volp ACP, Alfenas RCG, Costa NMB, Minim VPR, Stringueta PC, Bressan J. Capacidade dos Biomarcadores Inflamatórios em predizer a Síndrome Metabólica. Arq Bras Endocrinol Metab. 2008;52(3):537-49.

Svensson E, Mor A, Rungby J. Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort. BMC Endocr Disord. 2014;14:74.

Ohkuma T, Iwase M, Fujii H. Dose- and time-dependent association of smoking and its cessation with glycemic control and insulin resistance in male patients with type 2 diabetes mellitus: the fukuoka diabetes registry. PLoS One. 2015;10(3):e0122023.

Petkeviciene J, Klumbiene J, Kriaucioniene V, Raskiliene A, Sakyte E, Ceponiene I. Anthropometric measurements in childhood and prediction of cardiovascular risk factors in adulthood: Kaunas cardiovascular risk cohort study. BMC Public Health. 2015;15(1):218.

Lima LM, Carvalho MG, Vale AAL. Proteína C-reativa Ultra-sensível em pacientes com diagnóstico de doença arterial coronariana estabelecido por angiografia. J Bras Med Lab. 2007;43(2):83-6.

Silva IT, Sanches LB, Mello APQ, Damasceno NRT. Impacto da proteína C-reativa no risco cardiovascular de adolescentes. Arq Bras Cardiol. 2010;94(5):585-91.

Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-B transcription factor. Mol Cell Biol. 1990;10(5):2327-34.

Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 1997;272(26):16498-506.

Nowotny K, Jung T, Höhn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015;5(1):194-222.

Yamashita T, Sasaki N, Kasahara K, Hirata KI. Anti-inflammatory and immune-modulatory therapies for preventing atherosclerotic cardiovascular disease. J Cardiol. 2015;66(1):1-8.

Gremmel T, Perkmann T, Kopp CW. Interleukin-6 and asymmetric dimethylarginine are associated with platelet activation after percutaneous angioplasty with stent implantation. PLoS One. 2015;10(3):e0122586.

Junqueira ASM, Romêo Fo LJM, Junqueira CLC. Avaliação do grau de inflamação vascular em pacientes com síndrome metabólica. Arq Bras Cardiol. 2009;93(4):360-6.

Greenland P, Alpert JS, Beller GA. ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2010;122:e584-636.

Ridker PM, Danielson E, Fonseca FA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207.

Karaman S, Hollmén M, Robciuc MR. Blockade of VEGF-C and VEGF-D modulates adipose tissue inflammation and improves metabolic parameters under high-fat diet. Mol Metab. 2014;4(2):93-105.

Guimarães Fo GC, Sousa AL, Jardim TS. Progression of blood pressure and cardiovascular outcomes in hypertensive patients in a reference center. Arq Bras Cardiol. 2015;104(4):292-8.

Schmidt FM, Weschenfelder J, Sander C. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS One. 2015;10(3):e0121971.

Habich C, Sell H. Heat shock proteins in obesity: links to cardiovascular disease. Horm Mol Biol Clin Investig. 2015;21(2):117-24.

Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97.

Ringseis R, Eder K, Mooren FC, Krüger K. Metabolic signals and innate immune activation in obesity and exercise. Exerc Immunol Rev.. 2015;21:58-68.

Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175-84.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-808.

Gururajan P, Gurumurthy P, Nayar P. Increased serum concentrations of Soluble CD40 Ligand as a prognostic marker in patients with Acute Coronary Syndrome. Indian J Clin Biochem. 2009;24(3):229-33.

Tateya S, Kim F, Tamori Y. Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4:93.

Lacey DC, Achuthan A, Fleetwood AJ. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol. 2012;188(11):5752-65.

Schipper HS, Prakken B, Kalkhoven E, Boes M. Adipose tissue-resident immune cells: key players in immunometabolism. Trends Endocrinol Metab. 2012;23(8):407-15.

Shaharyar S, Roberson LL, Jamal O. Obesity and metabolic phenotypes (metabolically healthy and unhealthy variants) are significantly associated with prevalence of elevated c-reactive protein and hepatic steatosis in a large healthy Brazilian population. J Obes. 2015;2015:178526.

Sinha N, Dabla PK. Oxidative stress and antioxidants in hypertension - a current review. Curr Hypertens Rev. 2015;11(2):132-42.

Asare GA, Santa S, Ngala RA, Asiedu B, Afriyie D, Amoah AG. Effect of hormonal contraceptives on lipid profile and the risk indices for cardiovascular disease in a Ghanaian community. Int J Womens Health. 2014;2014(6):597-603.

Gomes F, Telo DF, Souza HP, Nicolau JC, Halpern A, Serrano Jr CV. Obesidade e doença arterial coronariana: papel da inflamação vascular. Arq Bras Cardiol.. 2010;94(2):273-9.

Alie N, Eldib M, Fayad ZA, Mani V. Inflammation, atherosclerosis, and coronary artery disease: PET/CT for the evaluation of atherosclerosis andinflammation. Clin Med Insights Cardiol. 2015;8(^sSupl 3):13-21.

Barbato JE, Tzeng E. Nitric oxide and arterial disease. J Vasc Surg. 2004;40(1):187-93.

Corrado E, Rizzo M, Coppola G. Na update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010;17(1):1-11.

Reinhart WH. Fibrinogen—marker or mediator of vascular disease?. Vasc Med. 2003;8(3):211-6.

Cao Y, Zhou X, Liu H, Zhang Y, Yu X, Liu C. The NF-κB pathway: regulation of the instability of atherosclerotic plaques activated by Fg, Fb, and FDPs. Mol Cell Biochem. 2013;383(1-2):29-37.

Vacek TP, Rehman S, Neamtu D, Yu S, Givimani S, Tyagi SC. Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms. Vasc Health Risk Manag. 2015;11:173-83.

Gargiulo S, Gamba P, Testa G. Relation between TLR4/NF-κB signaling pathway activation by 27-hydroxycholesterol and 4-hydroxynonenal, and atherosclerotic plaque instability. Aging Cell. 2015;14(4):569-81.

Donato AJ, Morgan RG, Walker AE, Lesniewski LA. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol. 2015.

Russo MA, Sansone L, Carnevale I. One special question to start with: can HIF/NFkB be a target in inflammation?. Endocr Metab Immune Disord Drug Targets. 2015;15(3):171-85.

Milam KE, Parikh SM. The angiopoietin-Tie2 signaling axis in the vascular leakage of systemic inflammation. Tissue Barriers. 2015;3(1-2):e957508.

Teixeira BC, Lopes AL, Macedo PDO. Inflammatory markers, endothelial function and cardiovascular risk. J Vasc Bras. 2014;13(2):108-15.

Masley SC, Roetzheim R, Masley LV, McNamara T, Schocken DD. Emerging risk factors as markers for carotid intima media thickness scores. J Am Coll Nutr. 2015;34(2):100-7.